Pharmacokinetics of acitretin
DOI:
https://doi.org/10.2340/00015555186122123Abstract
Acitretin, the metabolite of etretinate, is eliminated far more rapidly from the human body than is etretinate. It has therefore been suggested that only a short period of contraception would be required following the completion of long-term therapy. However, recent studies have demonstrated the presence of etretinate in the plasma of acitretin-treated patients. In this paper, we review the results of studies at our centre in view of the recently discovered metabolic pathways for acitretin. Re-esterification of acitretin to etretinate, however, results in a loss of the metabolic advantages of acitretin. Because of this new knowledge, the recommended contraception period after acitretin therapy has been lengthened to 2 years.Downloads
Download data is not yet available.
Downloads
Published
1994-02-01
How to Cite
Lambert, W., Meyer, E., De Leenheer, A., De Bersaques, J., & Kint, A. (1994). Pharmacokinetics of acitretin. Acta Dermato-Venereologica, 74, 122–123. https://doi.org/10.2340/00015555186122123
Issue
Section
Articles
License
LicenseAll digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
